About: SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity
Creator	Balani, Jyoti Li, Quan-Zhen Mahimainathan, Lenin Muthukumar, Alagarraju Sarode, Ravi Araj, Ellen Karp, David Lacelle, Chantale Markantonis, John Parikh, Hiren Phipps, William SoRelle, Jeffrey Solow, E
Source	Medline; PMC
abstract	OBJECTIVES: Initial reports indicate adequate performance of some serology-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course. METHODS: A total of 967 subjects were tested for IgG antibodies reactive to SARS-CoV-2, including 172 suspected cases of SARS-CoV-2, 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for polymerase chain reaction (PCR)–based respiratory viral panel. A subgroup of SARS-CoV-2 PCR-positive cases was tested for IgM antibodies by proteome array method. RESULTS: All specificity and cross-reactivity specimens were negative for SARS-CoV-2 IgG antibodies (0/795, 0%). Positive agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from symptom onset, with less than 100% sensitivity attributable to a case with severe immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course with respect to IgG and IgM levels. CONCLUSIONS: The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse cross-reactivity. Measures of IgG and IgM antibodies did not predict disease severity in our patient population.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1093/ajcp/aqaa123
bibo:pmid	32666092
has license	no-cc
schema:url	https://doi.org/10.1093/ajcp/aqaa123
resource representing a document's title	SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity
has PubMed Central identifier	PMC7454292
has PubMed identifier	32666092
schema:publication	Am J Clin Pathol
resource representing a document's body	covid:PMC7454292#body_text
is schema:about of	named entity 'Antibody' named entity 'PCR' named entity 'infection' named entity 'antibody response' named entity 'IgG' named entity 'lupus' named entity 'IgG' named entity 'negative result' named entity 'EDTA' named entity 'endemic' named entity 'ICU' named entity 'tested positive' named entity 'tested positive' named entity 'symptom' named entity 'seronegative' named entity 'PCR' named entity 'IgM' named entity 'IgG' named entity 'cross-reactivity' named entity 'PCR' named entity 'IgM' named entity 'respiratory illness' named entity 'nitrocellulose' named entity 'IgM' named entity 'significant difference' named entity 'false negative' named entity 'anti-dsDNA' named entity 'coronavirus' named entity 'IgG' named entity 'COVID' named entity 'virus' named entity 'infection' named entity 'proteome' named entity 'respiratory syncytial virus' named entity 'SARS-CoV-2' named entity 'China' named entity 'human coronaviruses' named entity 'intensive care' named entity 'plasma' named entity 'human coronavirus' named entity 'heparin' named entity 'insect' named entity 'antibody response' named entity 'SARS-CoV-2' named entity 'CMV' named entity 'symptom' named entity 'Roche' named entity 'life-threatening' named entity 'PCR' named entity 'long term' named entity 'IgG antibody' named entity 'IgG' named entity 'COVID-19' named entity 'symptom' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'rheumatoid arthritis' named entity 'blood donors' named entity 'long-term complications' named entity 'IgG' named entity 'seroconversion' named entity 'S/C' named entity 'PCR' named entity 'false positives' named entity 'PCR' named entity 'nasopharyngeal swab' named entity 'OC43' named entity 'IgG' named entity 'symptom' named entity 'IgG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software